177Lu-SN201
Spago takes Tumorad-01 study to the next level
Spago Nanomedical has increased the dose of its cancer drug candidate 177Lu-SN201 in its phase I/IIa Tumorad-01 study, following...
Spago's CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”
2024 has marked a defining chapter for Spago...
Spago's phase I/IIa cancer trial progressing steadily
The positive momentum for Spago Nanomedical carries over...
First patient dosed in Spago's phase I/IIa trial
Spago Nanomedical recently received approval to start the...
Spago Nanomedical's SAB on Tumorad's potential
Recently, Spago Nanomedical announced that the company has...
Spago Nanomedicals CDO on the study application
Spago Nanomedical recently submitted an application to...
Tumor clinical start around the corner for Spago Nanomedical
Encouraged by positive preclinical data with Tumorad, Spago...
Spago Nanomedical reports progress
ACS Omega
Spago Nanomedical publishes positive preclinical data
Preclinical data with Spago Nanomedical's radionuclide concept Tumorad has...
Spago Nanomedical starts phase IIa study in endometriosis
Lund-based Spago Nanomedical recently announced that the company has received...
Spago Nanomedical in hot area
Radionuclide therapies for cancer are a hot area that...
Spago Nanomedical about the autumn news flow
During the second quarter, the Lunda company Spago Nanomedical carried out a...